Market Place
Sourcing Support
Cognition CEO Participate in Longwood & Sachs Conferences
08 Jan 2025 //
GLOBENEWSWIRE
Cognition Therapeutics Reports Positive Ph 2 Results in Dementia
18 Dec 2024 //
GLOBENEWSWIRE
Cognition Therapeutics Completes Final Visits in Ph 2 Study
26 Nov 2024 //
GLOBENEWSWIRE
Cognition Biomarker Changes with Alzheimer’s Cognitive Benefit
25 Nov 2024 //
GLOBENEWSWIRE
Cognition Therapeutics Reports Q3 2024 Results & Updates
13 Nov 2024 //
GLOBENEWSWIRE
Cognition to Present at Zacks SCR Life Sciences Investor Forum
12 Nov 2024 //
GLOBENEWSWIRE
Cognition Therapeutics Presents Dementia Study Data at CTAD
31 Oct 2024 //
GLOBENEWSWIRE
Cognition Therapeutics Shares SHINE Study Analysis Results
29 Oct 2024 //
GLOBENEWSWIRE
Cognition Presents Phase 2 ‘SHINE’ Study Data at CTAD
23 Oct 2024 //
GLOBENEWSWIRE
Cognition Therapeutics Releases Podcast On Dementia Research
22 Oct 2024 //
GLOBENEWSWIRE
Cognition Therapeutics to Join Roth Healthcare Conference
02 Oct 2024 //
GLOBENEWSWIRE
Cognition Supports Lewy Body Dementia Awareness Month
01 Oct 2024 //
GLOBENEWSWIRE
Cognition Therapeutics to Attend September 2024 Investor Conferences
03 Sep 2024 //
GLOBENEWSWIRE
Cognition Therapeutics Publishes EEG Findings From CT1812 Study
22 Aug 2024 //
GLOBENEWSWIRE
Cognition Therapeutics Reports Q2 2024 Results And Business Update
08 Aug 2024 //
GLOBENEWSWIRE
Cognition Therapeutics to Report Second Quarter 2024 Financial Results
05 Aug 2024 //
GLOBENEWSWIRE
Cognition Therapeutics Reports Positive Phase 2 SHINE Trial Results
29 Jul 2024 //
GLOBENEWSWIRE
Cognition`s Alzheimer`s Drug Shows Mere `Signals` In Phase 2 SHINE Data
29 Jul 2024 //
FIERCE BIOTECH
Cognition Therapeutics To Discuss Phase 2 SHINE Study Results July 29
26 Jul 2024 //
GLOBENEWSWIRE
Cognition Therapeutics` CT1812 Study Results Accepted For AAIC Presentation
02 Jul 2024 //
GLOBENEWSWIRE
Cognition Releases Podcast On Alzheimer`s Amyloid Synapse Protection
21 May 2024 //
GLOBENEWSWIRE
Cognition Therapeutics Q1 2024 Results And Business Update
07 May 2024 //
GLOBENEWSWIRE
Cognition Completes Enrollment in SHIMMER Phase 2 for DLB
29 Apr 2024 //
GLOBENEWSWIRE
Cognition Discusses Alzheimer`s Treatment Options At KOL Event
22 Apr 2024 //
GLOBENEWSWIRE
Cognition Therapeutics to Present at the Needham Virtual Healthcare Conference
02 Apr 2024 //
GLOBENEWSWIRE
Cognition to host Virtual KOL Event on the Evolving Landscape in AD
01 Apr 2024 //
GLOBENEWSWIRE
Cognition Reports Year End 2023 Financial Results and Provides Business Update
26 Mar 2024 //
GLOBENEWSWIRE
Cognition Therapeutics to Report Fourth Quarter and Full Year 2023 Results
15 Mar 2024 //
GLOBENEWSWIRE
Cognition Announces Closing of $11.5 Million Public Offering of Common Stock
14 Mar 2024 //
GLOBENEWSWIRE
Cognition Therapeutics Announces Proposed Public Offering of Common Stock
11 Mar 2024 //
GLOBENEWSWIRE
Cognition Announces Pricing of $11.5 Million Public Offering of Common Stock
11 Mar 2024 //
GLOBENEWSWIRE
Cognition Therapeutics Presents Analyses at AD/PD 2024
06 Mar 2024 //
GLOBENEWSWIRE
Cognition Therapeutics to Present at the TD Cowen Health Care Conference
26 Feb 2024 //
GLOBENEWSWIRE
New Publication Identifies Key Proteins Involved in Amyloid Oligomer Binding
06 Feb 2024 //
GLOBENEWSWIRE
Cognition Therapeutics CEO Issues Letter to Shareholders
04 Jan 2024 //
GLOBENEWSWIRE
Cognition Therapeutics Releases New Episode of Conversations Podcast
16 Nov 2023 //
GLOBENEWSWIRE
Cognition Presents Data Identifying Pathways Impacted by Sigma-2 Modulators
15 Nov 2023 //
GLOBENEWSWIRE
Cognition Therapeutics Completes Enrollment in Phase 2 SHINE Study of CT1812
07 Nov 2023 //
GLOBENEWSWIRE
Cognition Therapeutics Reports Third Quarter 2023 Financial Results
02 Nov 2023 //
GLOBENEWSWIRE
Cognition Therapeutics Announce Presentation on the START Study
27 Oct 2023 //
GLOBENEWSWIRE
Cognition Presents Complete EEG Findings from SEQUEL Study of CT1812
24 Oct 2023 //
GLOBENEWSWIRE
Cognition Therapeutics Presents New Data at CTAD Conference
16 Oct 2023 //
GLOBENEWSWIRE
Cognition Announces Conversations Episode on Therapeutic Strategies
07 Sep 2023 //
GLOBENEWSWIRE
Cognition Therapeutics Announces Participation in Upcoming September Conferences
30 Aug 2023 //
GLOBENEWSWIRE
Cognition Therapeutics Reports Second Quarter 2023 Financial Results
08 Aug 2023 //
GLOBENEWSWIRE
Cognition Therapeutics to Report Second Quarter 2023 Results in Conference
02 Aug 2023 //
GLOBENEWSWIRE
Cognition Announces Dosing of First Patient in MAGNIFY Study of Oral CT1812
11 Jul 2023 //
GLOBENEWSWIRE
Cognition and Alzheimer`s Trials Initiate First Site in the Phase 2 START Study
05 Jul 2023 //
GLOBENEWSWIRE
Cognition Therapeutics slumps on Alzheimer`s drug study readout
29 Jun 2023 //
PRESS RELEASE
Cognition Therapeutics Announces +ve Topline Results for CT1812 Phase 2 SEQUEL
28 Jun 2023 //
GLOBENEWSWIRE
Cognition to Host Call and Webcast to Discuss Topline Results from CT1812 Ph 2
27 Jun 2023 //
GLOBENEWSWIRE
Cognition Invited to Participate Panel During Cantor Fitzgerald Brain Week 2023
20 Jun 2023 //
GLOBENEWSWIRE
Cognition Therapeutics Continues Investor Engagement in June
02 Jun 2023 //
GLOBENEWSWIRE
Cognition Publishes Clinical Evidence that CT1812 Displaces Oligomers
18 May 2023 //
GLOBENEWSWIRE
Cognition Therapeutics Reports 1Q 2023 FYR and Provides Business Update
04 May 2023 //
GLOBENEWSWIRE
Cognition Therapeutics Appoints John Doyle to the Role of CFO
01 May 2023 //
GLOBENEWSWIRE
Cognition Therapeutics to Present Analysis Showing Impact of CT1812
19 Apr 2023 //
GLOBENEWSWIRE
Cognition Announces Publication on Potential of Targeting Sigma-2 Receptor
12 Apr 2023 //
GLOBENEWSWIRE
Cognition Presents Biomarker Data Demonstrating Prominent Effects of CT1812
28 Mar 2023 //
GLOBENEWSWIRE
Cognition Therapeutics Announces New Episode of Conversations Podcast
27 Mar 2023 //
GLOBENEWSWIRE
